Alnylam Pharmaceuticals annual debt-to-equity ratio
2019
2020
2021
2024
2025
Alnylam Pharmaceuticals Debt-to-Equity Ratio Growth & History (ALNY)
Alnylam Pharmaceuticals's debt-to-equity ratio was 1.62 for fiscal 2025.
View full Alnylam Pharmaceuticals company overviewAlnylam Pharmaceuticals annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.62 | −17.70 | −91.61% |
| 2024 | 2024-12-31 | 19.32 | — | — |
| 2021 | 2021-12-31 | 0.55 | 0.03 | +6.71% |
| 2020 | 2020-12-31 | 0.51 | 0.30 | +142.85% |
| 2019 | 2019-12-31 | 0.21 | — | — |
Alnylam Pharmaceuticals quarterly debt-to-equity ratio
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.94 | −1.40 | −59.93% |
| Q1 2026 | 2026-03-31 | 1.18 | −1.87 | −61.24% |
| Q4 2025 | 2025-12-31 | 1.62 | −17.70 | −91.61% |
| Q3 2025 | 2025-09-30 | 5.59 | −34.64 | −86.10% |
| Q2 2025 | 2025-06-30 | 2.34 | — | — |
| Q1 2025 | 2025-03-31 | 3.05 | — | — |
| Q4 2024 | 2024-12-31 | 19.32 | — | — |
| Q3 2024 | 2024-09-30 | 40.24 | — | — |
| Q2 2022 | 2022-06-30 | 5.63 | 4.74 | +531.19% |
| Q1 2022 | 2022-03-31 | 2.48 | 1.92 | +343.20% |
| Q4 2021 | 2021-12-31 | 0.55 | 0.03 | +6.71% |
| Q3 2021 | 2021-09-30 | 1.01 | 0.73 | +271.02% |
| Q2 2021 | 2021-06-30 | 0.89 | 0.67 | +296.22% |
| Q1 2021 | 2021-03-31 | 0.56 | 0.33 | +147.89% |
| Q4 2020 | 2020-12-31 | 0.51 | 0.30 | +142.85% |
| Q3 2020 | 2020-09-30 | 0.27 | 0.08 | +43.05% |
| Q2 2020 | 2020-06-30 | 0.23 | 0.05 | +29.02% |
| Q1 2020 | 2020-03-31 | 0.23 | 0.03 | +16.74% |
| Q4 2019 | 2019-12-31 | 0.21 | — | — |
| Q3 2019 | 2019-09-30 | 0.19 | — | — |
| Q2 2019 | 2019-06-30 | 0.17 | — | — |
| Q1 2019 | 2019-03-31 | 0.19 | — | — |
Alnylam Pharmaceuticals debt-to-equity ratio trends
Over the last five fiscal years, Alnylam Pharmaceuticals's debt-to-equity ratio increased from 0.51 to 1.62, a change of 1.11. The latest reported quarter, Q2 2026, shows 0.94.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Alnylam Pharmaceuticals source filings ↗